Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry

Nanobodies, or single-domain antibodies (V<sub>H</sub>Hs) from camelid heavy-chain-only antibodies, offer significant advantages in therapeutic and diagnostic applications due to their small size and ability to bind cryptic protein epitopes inaccessible to conventional antibodies. In thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariam Maltseva, Martin A. Rossotti, Jamshid Tanha, Marc-André Langlois
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/17/4/571
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850180360442216448
author Mariam Maltseva
Martin A. Rossotti
Jamshid Tanha
Marc-André Langlois
author_facet Mariam Maltseva
Martin A. Rossotti
Jamshid Tanha
Marc-André Langlois
author_sort Mariam Maltseva
collection DOAJ
description Nanobodies, or single-domain antibodies (V<sub>H</sub>Hs) from camelid heavy-chain-only antibodies, offer significant advantages in therapeutic and diagnostic applications due to their small size and ability to bind cryptic protein epitopes inaccessible to conventional antibodies. In this study, we examined nanobodies specific to regions of the SARS-CoV-2 spike glycoprotein, including the receptor-binding domain (RBD), N-terminal domain (NTD), and subunit 2 (S2). Using flow virometry, a high-throughput technique for viral quantification, we achieved the efficient detection of pseudotyped viruses expressing the spike glycoprotein. RBD-targeting nanobodies showed the most effective staining, followed by NTD-targeting ones, while S2-specific nanobodies exhibited limited resolution. The simple genetic structure of nanobodies enables the creation of multimeric formats, improving binding specificity and avidity. Bivalent V<sub>H</sub>H-Fc constructs (V<sub>H</sub>Hs fused to the Fc region of human IgG) outperformed monovalent formats in resolving viral particles from background noise. However, S2-specific monovalent V<sub>H</sub>Hs demonstrated improved staining efficiency, suggesting their smaller size better accesses restricted antigenic sites. Furthermore, direct staining of cell supernatants was possible without virus purification. This versatile nanobody platform, initially developed for antiviral therapy against SARS-CoV-2, can be readily adapted for flow virometry applications and other diagnostic assays.
format Article
id doaj-art-0be1daab78eb4eec8f0dababf7da28d6
institution OA Journals
issn 1999-4915
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj-art-0be1daab78eb4eec8f0dababf7da28d62025-08-20T02:18:11ZengMDPI AGViruses1999-49152025-04-0117457110.3390/v17040571Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow VirometryMariam Maltseva0Martin A. Rossotti1Jamshid Tanha2Marc-André Langlois3Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, CanadaHuman Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, Ottawa, ON K1N 1J1, CanadaDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, CanadaDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, CanadaNanobodies, or single-domain antibodies (V<sub>H</sub>Hs) from camelid heavy-chain-only antibodies, offer significant advantages in therapeutic and diagnostic applications due to their small size and ability to bind cryptic protein epitopes inaccessible to conventional antibodies. In this study, we examined nanobodies specific to regions of the SARS-CoV-2 spike glycoprotein, including the receptor-binding domain (RBD), N-terminal domain (NTD), and subunit 2 (S2). Using flow virometry, a high-throughput technique for viral quantification, we achieved the efficient detection of pseudotyped viruses expressing the spike glycoprotein. RBD-targeting nanobodies showed the most effective staining, followed by NTD-targeting ones, while S2-specific nanobodies exhibited limited resolution. The simple genetic structure of nanobodies enables the creation of multimeric formats, improving binding specificity and avidity. Bivalent V<sub>H</sub>H-Fc constructs (V<sub>H</sub>Hs fused to the Fc region of human IgG) outperformed monovalent formats in resolving viral particles from background noise. However, S2-specific monovalent V<sub>H</sub>Hs demonstrated improved staining efficiency, suggesting their smaller size better accesses restricted antigenic sites. Furthermore, direct staining of cell supernatants was possible without virus purification. This versatile nanobody platform, initially developed for antiviral therapy against SARS-CoV-2, can be readily adapted for flow virometry applications and other diagnostic assays.https://www.mdpi.com/1999-4915/17/4/571flow virometrynanobodiesdiagnosticsantiviralsSARS-CoV-2
spellingShingle Mariam Maltseva
Martin A. Rossotti
Jamshid Tanha
Marc-André Langlois
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
Viruses
flow virometry
nanobodies
diagnostics
antivirals
SARS-CoV-2
title Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
title_full Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
title_fullStr Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
title_full_unstemmed Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
title_short Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry
title_sort characterization of nanobody binding to distinct regions of the sars cov 2 spike protein by flow virometry
topic flow virometry
nanobodies
diagnostics
antivirals
SARS-CoV-2
url https://www.mdpi.com/1999-4915/17/4/571
work_keys_str_mv AT mariammaltseva characterizationofnanobodybindingtodistinctregionsofthesarscov2spikeproteinbyflowvirometry
AT martinarossotti characterizationofnanobodybindingtodistinctregionsofthesarscov2spikeproteinbyflowvirometry
AT jamshidtanha characterizationofnanobodybindingtodistinctregionsofthesarscov2spikeproteinbyflowvirometry
AT marcandrelanglois characterizationofnanobodybindingtodistinctregionsofthesarscov2spikeproteinbyflowvirometry